Enable injections, Inc., a Cincinnati-based company that develops and manufactures the enFuse platform for investigational wearable drug delivery systems, has raised $215m through Series C financing.
Magnetar Capital led the round with participation from existing investors Cincinnati Children’s Hospital Medical Center (CincyTech), Cintrifuse and Ohio Innovation Fund.
Led by Mike Hooven, President and CEO, Enable Injections is an investigational-stage company developing and manufacturing on-body subcutaneous drug delivery systems designed to improve the patient experience, and advance healthcare system value and economics. The body-worn enFuse (r), drug delivery platform uses standard container closures to deliver high volumes of pharmaceutical and biologic therapeutics.
The company plans to use the funds for the global expansion of the enFuse platform.